Samra A, Radoua A, Tanaydin ES, Alrustom B, Bordessoules M, Fischer T, Callot M, Georgsson S, Rávai B, Mátravölgyi B, Bálint E, Eriksson LA, Chluba J, Plenchette S, Micheau O

Methods Cell Biol. 2026 03 12;206:125-143

Efficient generation of isogenic FADD, RIPK1 and Caspase-8 cells using a the ptARgenOM non-viral CRISPR-Cas9 system.

Radoua A, Alrustom B, Wang J, Bordessoules M, Chluba J, Plenchette S, Micheau O

Methods Cell Biol. 2026 03 9;208:115-147

TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.

Guerrache A, Micheau O

Cells. 2024 03 16;13(6):

Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.

Groeneveld CS, Sanchez-Quiles V, Dufour F, Shi M, Dingli F, Nicolle R, Chapeaublanc E, Poullet P, Jeffery D, Krucker C, Maillé P, Vacherot F, Vordos D, Benhamou S, Lebret T, Micheau O, Zinovyev A, Loew D, Allory Y, de Reyniès A, Bernard-Pierrot I, Radvanyi F

Eur Urol. 2023 06 27;:

ptARgenOM-A Flexible Vector For CRISPR/CAS9 Nonviral Delivery.

Radoua A, Pernon B, Pernet N, Jean C, Elmallah M, Guerrache A, Constantinescu AA, Hadj Hamou S, Devy J, Micheau O

Small Methods. 2023 05 8;:e2300069

Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network.

Ichim G, Gibert B, Adriouch S, Brenner C, Davoust N, Desagher S, Devos D, Dokudovskaya S, Dubrez L, Estaquier J, Gillet G, Guénal I, Juin PP, Kroemer G, Legembre P, Levayer R, Manon S, Mehlen P, Meurette O, Micheau O, Mignotte B, Nguyen-Khac F, Popgeorgiev N, Poyet JL, Priault M, Ricci JE, Riquet FB, Susin SA, Suzanne M, Vacher P, Walter L, Mollereau B

Biomolecules. 2022 06 28;12(7):

TRAIL Triggers CRAC-Dependent Calcium Influx and Apoptosis through the Recruitment of Autophagy Proteins to Death-Inducing Signaling Complex.

Airiau K, Vacher P, Micheau O, Prouzet-Mauleon V, Kroemer G, Moosavi MA, Djavaheri-Mergny M

Cells. 2021 Dec 25;11(1):

Pharmacological Investigation of CC-LAAO, an L-Amino Acid Oxidase from Snake Venom.

Abdelkafi-Koubaa Z, ELBini-Dhouib I, Souid S, Jebali J, Doghri R, Srairi-Abid N, Essafi-Benkhadir K, Micheau O, Marrakchi N

Toxins (Basel). 2021 Dec 16;13(12):

Neutral sphingomyelinase 2 heightens anti-melanoma immune responses and anti-PD-1 therapy efficacy.

Montfort A, Bertrand F, Rochotte J, Gilhodes J, Filleron T, Milhès J, Dufau C, Imbert C, Riond J, Tosolini M, Clarke CJ, Dufour F, Constantinescu AA, de França Junior N, Garcia V, Record M, Cordelier P, Brousset P, Rochaix P, Silvente-Poirot S, Therville N, Andrieu-Abadie N, Levade T, Hannun YA, Benoist H, Meyer N, Micheau O, Colacios C, Ségui B

Cancer Immunol Res. 2021 Mar 16;:

Grafting TRAIL through Either Amino or Carboxylic Groups onto Maghemite Nanoparticles: Influence on Pro-Apoptotic Efficiency.

Belkahla H, Constantinescu AA, Gharbi T, Barbault F, Chevillot-Biraud A, Decorse P, Micheau O, Hémadi M, Ammar S

Nanomaterials (Basel). 2021 Feb 17;11(2):

Editorial: TNFR Superfamily Oligomerization and Signaling.

Micheau O, Rizzi M, Smulski CR

Front Cell Dev Biol. 2021 ;9:682472

The multifaceted role of TRAIL signaling in cancer and immunity.

Cardoso Alves L, Corazza N, Micheau O, Krebs P

FEBS J. 2020 Nov 20;:

Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP.

Elmallah MIY, Cogo S, Constantinescu AA, Elifio-Esposito S, Abdelfattah MS, Micheau O

Cells. 2020 Jul 22;9(8):

Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.

Vanbervliet-Defrance B, Delaunay T, Daunizeau T, Kepenekian V, Glehen O, Weber K, Estornes Y, Ziverec A, Djemal L, Delphin M, Lantuéjoul S, Passot G, Grégoire M, Micheau O, Blanquart C, Renno T, Fonteneau JF, Lebecque S, Mahtouk K

Cancer Lett.. 2019 Dec 12;:

Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy.

Elmallah MIY, Micheau O

Cancers (Basel). 2019 Jun 19;11(6):

Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.

Dubuisson A, Favreau C, Fourmaux E, Lareure S, Rodrigues-Saraiva R, Pellat-Deceunynck C, El Alaoui S, Micheau O

Cell Death Dis. 2019 Feb 4;10(2):101

TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia.

Belkahla H, Mazarío E, Sangnier AP, Lomas JS, Gharbi T, Ammar S, Micheau O, Wilhelm C, Hémadi M

Theranostics. 2019 ;9(20):5924-5936

Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.

Alkurdi L, Virard F, Vanbervliet B, Weber K, Toscano F, Bonnin M, Le Stang N, Lantuejoul S, Micheau O, Renno T, Lebecque S, Estornes Y

Cell Death Dis. 2018 Aug 29;9(9):874

The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death.

Vial J, Royet A, Cassier P, Tortereau A, Dinvaut S, Maillet D, Gratadou-Hupon L, Creveaux M, Sadier A, Tondeur G, Léon S, Depaepe L, Pantalacci S, de la Fouchardière A, Micheau O, Dalle S, Laudet V, Mehlen P, Castets M

Cell Death Differ.. 2018 May 31;:

Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes.

Chekkat N, Lombardo CM, Seguin C, Lechner MC, Dufour F, Nominé Y, De Giorgi M, Frisch B, Micheau O, Guichard G, Altschuh D, Fournel S

Oncotarget. 2018 Mar 20;9(21):15566-15578

Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation.

Micheau O

Int J Mol Sci. 2018 Mar 2;19(3):

Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy.

Dubuisson A, Micheau O

Antibodies (Basel). 2017 Oct 25;6(4):

DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.

Glorian V, Allègre J, Berthelet J, Dumetier B, Boutanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Marcion G, Gonzalez D, Boidot R, Garrido C, Michaud O, Solary E, Dubrez L

Cell Death Dis. 2017 May;8(5):e2816

Marine actinomycete crude extracts with potent TRAIL-resistance overcoming activity against breast cancer cells.

Elmallah MIY, Micheau O, Eid MAG, Hebishy AMS, Abdelfattah MS

Oncol. Rep.. 2017 Apr;:

TRAIL-NP hybrids for cancer therapy: a review.

Belkahla H, Herlem G, Picaud F, Gharbi T, Hémadi M, Ammar S, Micheau O

Nanoscale. 2017 Apr;:

N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.

Dufour F, Rattier T, Shirley S, Picarda G, Constantinescu AA, Morlé A, Zakaria AB, Marcion G, Causse S, Szegezdi E, Zajonc DM, Seigneuric R, Guichard G, Gharbi T, Picaud F, Herlem G, Garrido C, Schneider P, Benedict CA, Micheau O

Cell Death Differ.. 2017 Mar;24(3):500-510

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress.

Dufour F, Rattier T, Constantinescu AA, Zischler L, Morlé A, Ben Mabrouk H, Humblin E, Jacquemin G, Szegezdi E, Delacote F, Marrakchi N, Guichard G, Pellat-Deceunynck C, Vacher P, Legembre P, Garrido C, Micheau O

Oncotarget. 2017 Feb;8(6):9974-9985

Immunoprecipitation of Death Inducing Signaling Complex by Caspase-8.

Constantinescu AA, Morlé A, Micheau O

Methods Mol. Biol.. 2017 ;1557:19-31

Enhanced DR5 binding capacity of nanovectorized TRAIL compared to its cytotoxic version by affinity chromatography and molecular docking studies.

Zakaria A, Picaud F, Guillaume YC, Gharbi T, Micheau O, Herlem G

J. Mol. Recognit.. 2016 Sep;29(9):406-14

The mycotoxin zearalenone enhances cell proliferation, colony formation and promotes cell migration in the human colon carcinoma cell line HCT116.

Abassi H, Ayed-Boussema I, Shirley S, Abid S, Bacha H, Micheau O

Toxicol. Lett.. 2016 Jul;254:1-7

CC5 and CC8, two homologous disintegrins from Cerastes cerastes venom, inhibit in vitro and ex vivo angiogenesis.

Ben-Mabrouk H, Zouari-Kessentini R, Montassar F, Koubaa ZA, Messaadi E, Guillonneau X, ElAyeb M, Srairi-Abid N, Luis J, Micheau O, Marrakchi N

Int. J. Biol. Macromol.. 2016 May;86:670-80

Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility.

Edmond V, Dufour F, Poiroux G, Shoji K, Malleter M, Fouque A, Tauzin S, Rimokh R, Sergent O, Penna A, Dupuy A, Levade T, Theret N, Micheau O, Segui B, Legembre P

Oncogene. 2015 Feb 19;34(8):996-1005

Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells.

Iessi E, Zischler L, Etringer A, Bergeret M, Morle A, Jacquemin G, Morizot A, Shirley S, Lalaoui N, Elifio-Esposito SL, Fais S, Garrido C, Solary E, Micheau O

PLoS One. 2015 May 26;10(5):e0126526

Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion.

Morle A, Garrido C, Micheau O

Cell Death Dis. 2015 Feb 12;6:e1633

Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).

Elmallah MI, Micheau O

Mar Drugs. 2015 Nov 13;13(11):6884-909

Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing.

Zakaria AB, Picaud F, Rattier T, Pudlo M, Saviot L, Chassagnon R, Lherminier J, Gharbi T, Micheau O, Herlem G

Nano Lett. 2015 Jan 13.

Sphingolipids modulate the epithelial-mesenchymal transition in cancer.

Levade T, Andrieu-Abadie N, Micheau O, Legembre P, Ségui B

Cell Death Discov. 2015 ;1:15001

Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells.

de Thonel A, Hazoume A, Kochin V, Isoniemi K, Jego G, Fourmaux E, Hammann A, Mjahed H, Filhol O, Micheau O, Rocchi P, Mezger V, Eriksson JE, Rangnekar VM, Garrido C

Cell Death Dis. 2014 Jan 23;5:e1016

Death receptors as targets in cancer.

Micheau O, Shirley S, Dufour F

Br J Pharmacol. 2013 Aug;169(8):1723-44

Targeting c-FLIP in cancer.

Shirley S, Micheau O

Cancer Lett. 2013 May 28;332(2):141-50

Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation.

Wettstein G, Bellaye PS, Kolb M, Hammann A, Crestani B, Soler P, Marchal-Somme J, Hazoume A, Gauldie J, Gunther A, Micheau O, Gleave M, Camus P, Garrido C, Bonniaud P

FASEB J.. 2013 Apr;27(4):1549-60

TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis.

Somasekharan SP, Koc M, Morizot A, Micheau O, Sorensen PH, Gaide O, Andera L, Martinou JC

Apoptosis. 2013 Mar;18(3):324-36

Small heat shock proteins and the cytoskeleton: an essential interplay for cell integrity?

Wettstein G, Bellaye PS, Micheau O, Bonniaud P

Int J Biochem Cell Biol. 2012 Oct;44(10):1680-6

dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8.

Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet B, Bonnin M, Lalaoui N, Mercier-Gouy P, Pacheco Y, Salaun B, Renno T, Micheau O, Lebecque S

Cell Death Differ. 2012 Sep;19(9):1482-94

Thiocolchicoside a semi-synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption?

Micheau O, Dufour F, Walczak H

Br J Pharmacol. 2012 Apr;165(7):2124-6

Identification of a novel pro-apoptotic role of NF-kappaB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells.

Jennewein C, Karl S, Baumann B, Micheau O, Debatin KM, Fulda S

Oncogene. 2012 Mar 15;31(11):1468-74

Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.

Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morle A, Iessi E, Morizot A, Garrido C, Guillaudeux T, Micheau O

Haematologica. 2012 Jan;97(1):38-46

Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion.

Shirley S, Morizot A, Micheau O

Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):311-23

Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.

El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC

Gastroenterology. 2011 Aug;141(2):663-73

Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Morizot A, Merino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, Lanneau D, Bouyer F, Solary E, Chauffert B, Saas P, Garrido C, Micheau O

Cell Death Differ. 2011 Apr;18(4):700-11

Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy.

Rerole AL, Gobbo J, De Thonel A, Schmitt E, Pais de Barros JP, Hammann A, Lanneau D, Fourmaux E, Deminov O, Micheau O, Lagrost L, Colas P, Kroemer G, Garrido C

Cancer Res. 2011 Jan 15;71(2):484-95

TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.

Lalaoui N, Morle A, Merino D, Jacquemin G, Iessi E, Morizot A, Shirley S, Robert B, Solary E, Garrido C, Micheau O

PLoS One. 2011;6(5):e19679

Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Jacquemin G, Shirley S, Micheau O

Cell Mol Life Sci. 2010 Sep;67(18):3115-30

Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.

Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M, Maison W, Fournel S, Micheau O, Guichard G, Gronemeyer H

Cancer Res. 2010 Feb 1;70(3):1101-10

Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells.

Fraszczak J, Trad M, Janikashvili N, Cathelin D, Lakomy D, Granci V, Morizot A, Audia S, Micheau O, Lagrost L, Katsanis E, Solary E, Larmonier N, Bonnotte B

J Immunol. 2010 Feb 15;184(4):1876-84